SCHEMBL2208249

SCHEMBL2208249

CN1CCn2c(nc(C(=O)NCc3ccc(F)cc3)c(O)c2=O)C(NC(=O)C(=O)N(C)C)C1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.62
KCNH2 Q12809 1/20 0.56
SMN1; SMN2 Q16637 2/20 0.40
KCNE1 P15382 1/20 0.40
CCR1 P32246 1/20 0.40
KCNQ1 P51787 1/20 0.40
CALCA P06881 1/20 0.39
ERCC1 P07992 1/20 0.38
FEN1 P39748 1/20 0.38
ERCC4 Q92889 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
GAA P10253 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2206033 0.89 KCNH2 (0.55) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL2207787 0.86 CYP2C9 (0.78) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL2204581 0.84 KCNH2 (0.54) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL2208851 0.84 KCNH2 (0.54) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL2208054 0.84 KCNH2 (0.58) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL2208609 0.84 CYP2C9 (0.67) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL12433081 0.83 KCNH2 (0.59) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL2207621 0.82 CYP2C9 (0.65) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL4505298 0.82 CYP2C9 (0.65) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1
SCHEMBL2206782 0.82 CYP2C9 (0.58) CYP2C9KCNH2SMN1; SMN2KCNE1CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257162-A1 HIV INTEGRASE INHIBITORS SUMMA VINCENZO 2011-10-20 US claimed
US-20090253681-A1 HIV Integrase Inhibitors MSD ITALIA S.R.L. (IT) 2009-10-08 US claimed
US-20110257162-A1 HIV INTEGRASE INHIBITORS SUMMA VINCENZO 2011-10-20 US disclosed
US-20110257162-A1 HIV INTEGRASE INHIBITORS SUMMA VINCENZO 2011-10-20 US disclosed
US-7981879-B2 HIV integrase inhibitors Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) 2011-07-19 US disclosed
US-7981879-B2 HIV integrase inhibitors Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) 2011-07-19 US disclosed
US-7981879-B2 HIV integrase inhibitors Instituto di Ricerchi di Biologia Molecolare P. Angeletti S.p.A. (IT) 2011-07-19 US disclosed
US-20090253681-A1 HIV Integrase Inhibitors MSD ITALIA S.R.L. (IT) 2009-10-08 US disclosed
US-20090253681-A1 HIV Integrase Inhibitors MSD ITALIA S.R.L. (IT) 2009-10-08 US disclosed
US-20090253681-A1 HIV Integrase Inhibitors MSD ITALIA S.R.L. (IT) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257162-A1 HIV INTEGRASE INHIBITORS REV1, CDK9, INTS9 CYP2C9 672/4885KCNH2 2918/4885SMN1; SMN2 2699/4885
US-20090253681-A1 HIV Integrase Inhibitors REV1, INTS9, H1-10 CYP2C9 449/4885KCNH2 3625/4885SMN1; SMN2 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.